摘要
目的探讨达比加群酯治疗恶性肿瘤合并下肢深静脉血栓形成的临床疗效。方法将70例恶性肿瘤合并下肢静脉血栓形成患者按随机数字表法分为观察组和对照组,每组35例。观察组采用达比加群酯胶囊治疗,对照组采用华法林钠片治疗。观察2组治疗前、治疗1个月后血流速度、下肢周径差、INR、纤维蛋白原(FIB)、D-二聚体(D-D)水平和凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、凝血酶时间(TT)及临床疗效、不良反应发生率。结果观察组总有效率明显高于对照组(P<0.05)。2组治疗1个月后血流速度、下肢周径差与治疗前比较差异有统计学意义(P<0.05),观察组治疗1个月后血流速度、下肢周径差与对照组比较差异有统计学意义(P<0.05)。观察组治疗1个月后APTT、PT、TT和INR、FIB、D-D水平与对照组比较差异有统计学意义(P<0.05)。观察组出血发生率明显低于对照组(P<0.05)。结论达比加群酯治疗恶性肿瘤合并下肢深静脉血栓形成具有显著疗效,能够降低不良反应发生率。
Objective To investigate the clinical effect of dabigatran etexilate on malignant tumor complicated by lower extremity deep venous thrombosis（DVT）.Methods Seventy patients with malignant tumor complicated by lower extremity DVT were randomly assigned to receive either dabigatran etexilate capsules（observation group,n=35）or warfarin sodium tablets（control group,n=35）.Blood flow velocity,lower limb circumference difference,international normalized ratio（INR）,fibrinogen（FIB）,D-dimer（D-D）,prothrombin time（PT）,activated partial thromboplastin time（APTT）and thrombin time（TT）were measured before and after treatment for 1month.In addition,clinical efficacy and incidence of adverse events were compared between the two groups.Results The total effective rate in observation group was significantly higher than that in control group（P〈0.05）.After treatment for 1month,blood flow velocity and lower limb circumference difference were significantly improved in both groups（P〈0.05）.Furthermore,there were significant differences in blood flow velocity,lower limb circumference difference,APTT,PT,TT,INR,FIB and D-D between the two groups after treatment for 1 month（P〈0.05）.The incidence of bleeding in observation group was significantly lower than that in control group（P〈0.05）.Conclusion Dabigatran etexilate is effective for malignant tumor complicated by lower extremity DVT and can reduce the incidence of adverse events.
出处
《实用临床医学（江西）》
CAS
2017年第6期1-3,6,共4页
Practical Clinical Medicine
基金
深圳市福田区卫生公益性科研项目(FTWS20160014)
关键词
恶性肿瘤
下肢深静脉血栓形成
达比加群酯
华法令钠
疗效
安全
malignant tumor
lower extremity deep venous thrombosis
dabigatran etexilate
warfarin sodium
clinical effect
safety
